|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We report that NO66 levels were upregulated in advanced primary prostate tumors compared to normal tissue or tumors with low Gleason scores.
|
30858546 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Low expression levels of SMYD2, SETD3, and NO66 were significantly associated with shorter disease-specific and disease-free survival, especially in patients with non-organ confined tumors.
|
26488939 |
2015 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Despite experimental evidence that ROX might act as a tumor suppressor gene, our data suggest that mutations in the coding region of ROX are uncommon in human breast tumorigenesis.
|
9598315 |
1998 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We conclude that ROX/Mnt itself is not a frequent target for 17p13.3 deletions in lung cancers and that further explorations are required to identify the putative tumor suppressor gene at 17p13.3.
|
9617337 |
1998 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Our findings uncover the role of NO66 as a key oncogenic driver in PCa, causing osteolytic lesions through upstream epigenetic regulation of key genes for survival, invasion and metastasis, and pro-osteoclastic factors.
|
30858546 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The cancer-selective expression patterns and its involvement in metastatic phenotypes suggest that NO66 is not only a crucial biomarker but is also a promising therapeutic target in CRC.
|
27473587 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, high expression levels of NO66 were associated with cancer metastatic potential, including lymphatic duct invasion (p = 0.047), venous invasion (p = 0.033), and lymph node metastasis (p = 0.015).
|
27473587 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The results showed that Rictor mRNA expression of EC is higher than that of normal endometrium; Rictor protein expression level was closely correlated with FIGO stage, grade and vascular invasion in both cohorts; a univariate analysis showed that the pathological type, stage, grade, vascular invasion, lymphatic metastasis and Rictor were predictors of OS in both cohorts; furthermore, multivariate Cox proportional hazards regression analysis indicated that vascular invasion and Rictor were independent prognostic factors for EC in both cohorts; an ROX curve comparison showed that the area under the curve (AUC) for Rictor combined with other clinicopathological prognostic factors was higher than any individual factor or other clinicopathological prognostic factors' combination.
|
24966915 |
2014 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
This is the first report to show that Mad1, Mxi1 and Rox genes were expressed and displayed mutations in haematological malignancies.
|
17577784 |
2007 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The ROX gene maps to chromosome 17p13.3, a region frequently deleted in human malignancies.
|
9598315 |
1998 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
As our data imply that MAPJD is a novel member of the MYC transcriptional complex and its activation is a common feature of lung cancer, selective suppression of this pathway could be a promising therapeutic target for treatment of lung cancers.
|
17308053 |
2007 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
We conclude that ROX/Mnt itself is not a frequent target for 17p13.3 deletions in lung cancers and that further explorations are required to identify the putative tumor suppressor gene at 17p13.3.
|
9617337 |
1998 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of NO66 in glioma and glioblastoma tissues predict poor patient prognosis, and NO66 is required for EGFR expression and glioblastoma cell proliferation.
|
31704826 |
2019 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of NO66 in glioma and glioblastoma tissues predict poor patient prognosis, and NO66 is required for EGFR expression and glioblastoma cell proliferation.
|
31704826 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our findings uncover the role of NO66 as a key oncogenic driver in PCa, causing osteolytic lesions through upstream epigenetic regulation of key genes for survival, invasion and metastasis, and pro-osteoclastic factors.
|
30858546 |
2019 |
|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
NO66-overexpressing PC3 cells implanted into the femoral bone of male SCID mice caused massive bone loss and stimulation of mouse osteoclast-promoting genes, including Dickkopf1, Cathepsin K, Nf-kβ,; and Calcr, suggesting a role for NO66 in tumor growth in bone and osteoclast activity.
|
30858546 |
2019 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We report that NO66 levels were upregulated in advanced primary prostate tumors compared to normal tissue or tumors with low Gleason scores.
|
30858546 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we explored the role of histone demethylase NO66 in the pathogenesis of PCa and bone metastasis-related skeletal lesions.
|
30858546 |
2019 |
|
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of NO66 in glioma and glioblastoma tissues predict poor patient prognosis, and NO66 is required for EGFR expression and glioblastoma cell proliferation.
|
31704826 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of NO66 in glioma and glioblastoma tissues predict poor patient prognosis, and NO66 is required for EGFR expression and glioblastoma cell proliferation.
|
31704826 |
2019 |
|
Hormone refractory prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
|
30858546 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of NO66 in glioma and glioblastoma tissues predict poor patient prognosis, and NO66 is required for EGFR expression and glioblastoma cell proliferation.
|
31704826 |
2019 |
|
androgen independent prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Combined RNAseq and ChIP-seq revealed that NO66 activates the survival gene MCL1, the invasion-associated genes IGFBP5 and MMP3, the pro-oncogenic genes CTNNB1 and CCND1, and the epigenetic modifier gene KMT2A in androgen-independent PCa.
|
30858546 |
2019 |
|
Ankylosing spondylitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sub‑pathways, including the MAPK signaling pathway and chemokine signaling pathway, and hub lncRNA (C14orf169) may serve important roles in SpA/AS.
|
30132545 |
2018 |
|
Anastomosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Preliminary data using the ROX coupler to form a central arteriovenous anastomosis are very encouraging.
|
29084002 |
2018 |